HeartBeam, Inc. (NASDAQ: BEAT), a pioneering medical technology company revolutionizing cardiac care, has closed its $10 million public offering, marking a significant milestone in its commercialization journey. The transaction, which included 5,882,353 shares of common stock priced at $1.70 per share, strengthens the company’s position following its recent FDA clearance for its comprehensive arrhythmia assessment system.
Lucosky Brookman LLP served as legal counsel to HeartBeam in this strategic financing, which bolsters the company’s ability to advance its groundbreaking cardiac monitoring technology. The offering included a 45-day option for the underwriter to purchase up to an additional 882,353 shares to cover over-allotments.
